Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

Study identifier:H8O-MC-GWAK

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Exploratory Study of the Safety of Substituting Exenatide for Insulin in Patients With Type 2 Diabetes Who Have Been Using Insulin in Combination With Oral Antidiabetic Therapy

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 2

Healthy volunteers

No

Study drug

exenatide, Insulin

Sex

All

Actual Enrollment

49

Study type

Interventional

Age

35 Years - 70 Years

Date

Study Start Date: 01 Feb 2004
Primary Completion Date: 01 Aug 2005
Study Completion Date: 01 Aug 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria